Literature DB >> 7588088

Guidelines for the use of zidovudine in pregnant women with HIV infection.

M De Santis1, G Noia, A Caruso, S Mancuso.   

Abstract

Zidovudine therapy seems to be effective for reducing vertical transmission of HIV infection and preventing paediatric AIDS. Besides those cases in which it is indicated, zidovudine plays an important role in safeguarding maternal well-being. Even though no data indicating teratogenic effect of this drug exist, its use during the first trimester should be limited to those cases where it is absolutely indicated. All undergoing this therapy should be informed that no information regarding the long term effects of this drug are available yet. Further controlled studies are necessary if this drug is to be used in those cases where it could actually be of benefit.

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 7588088     DOI： 10.2165/00003495-199550010-00004

Source DB:  PubMed          Journal:  Drugs        ISSN： 0012-6667            Impact factor:   9.546


  25 in total

1.  Zidovudine-associated embryonic toxicity in mice.

Authors:  P Toltzis; C M Marx; N Kleinman; E M Levine; E V Schmidt
Journal:  J Infect Dis       Date:  1991-06       Impact factor: 5.226

2.  Pharmacokinetics of azidothymidine during late pregnancy in Long-Evans rats.

Authors:  B B Little; R E Bawdon; J T Christmas; S Sobhi; L C Gilstrap
Journal:  Am J Obstet Gynecol       Date:  1989-09       Impact factor: 8.661

3.  Severe polymyositis-like syndrome associated with zidovudine therapy of AIDS and ARC.

Authors:  L J Bessen; J B Greene; E Louie; P Seitzman; H Weinberg
Journal:  N Engl J Med       Date:  1988-03-17       Impact factor: 91.245

4.  Significant changes in HIV antigen level in the serum of patients treated with azidothymidine.

Authors:  R E Chaisson; J P Allain; M Leuther; P A Volberding
Journal:  N Engl J Med       Date:  1986-12-18       Impact factor: 91.245

5.  Perinatal pharmacokinetics of zidovudine.

Authors:  P Chavanet; B Diquet; A Waldner; H Portier
Journal:  N Engl J Med       Date:  1989-11-30       Impact factor: 91.245

6.  Azidothymidine (zidovudine) transport by the human placenta.

Authors:  S Schenker; R F Johnson; T S King; R S Schenken; G I Henderson
Journal:  Am J Med Sci       Date:  1990-01       Impact factor: 2.378

7.  The pharmacokinetics and safety of zidovudine in the third trimester of pregnancy for women infected with human immunodeficiency virus and their infants: phase I acquired immunodeficiency syndrome clinical trials group study (protocol 082). Zidovudine Collaborative Working Group.

Authors:  M J O'Sullivan; P J Boyer; G B Scott; W P Parks; S Weller; M R Blum; J Balsley; Y J Bryson
Journal:  Am J Obstet Gynecol       Date:  1993-05       Impact factor: 8.661

Review 8.  Treatment options for human immunodeficiency virus-infected pregnant women. Obstetric-Gynecologic Working Group of the AIDS Clinical Trials Group of the National Institute of Allergy and Infectious Diseases.

Authors:  R S Sperling; P Stratton
Journal:  Obstet Gynecol       Date:  1992-03       Impact factor: 7.661

9.  Amelioration of zidovudine-induced fetal toxicity in pregnant mice.

Authors:  S R Gogu; B S Beckman; K C Agrawal
Journal:  Antimicrob Agents Chemother       Date:  1992-11       Impact factor: 5.191

10.  Zidovudine in asymptomatic human immunodeficiency virus infection. A controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. The AIDS Clinical Trials Group of the National Institute of Allergy and Infectious Diseases.

Authors:  P A Volberding; S W Lagakos; M A Koch; C Pettinelli; M W Myers; D K Booth; H H Balfour; R C Reichman; J A Bartlett; M S Hirsch
Journal:  N Engl J Med       Date:  1990-04-05       Impact factor: 91.245
View more
  1 in total

1.  Glucuronidation of 3'-azido-3'-deoxythymidine (zidovudine) by human liver microsomes: relevance to clinical pharmacokinetic interactions with atovaquone, fluconazole, methadone, and valproic acid.

Authors:  C B Trapnell; R W Klecker; C Jamis-Dow; J M Collins
Journal:  Antimicrob Agents Chemother       Date:  1998-07       Impact factor: 5.191
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.